Kombo knife combined with sorafenib in liver cancer treatment: Efficacy and safety under immune function influence

Figure 7 The effects of peripheral blood mononuclear cells with increased immune function on hepatocellular carcinoma cells. A: Optical microscopy images of JHH7 and HuH7 cells cocultured with peripheral blood mononuclear cells (PBMCs) from posttreatment patients for 24 h. Arrows indicate tumor cells; Bar = 100 μm; B: Transwell plate culture of tumor colony formation after 24 h of coculture of JHH7 and HuH7 cells with PBMCs from posttreatment patients; C: Quantification of tumor colony numbers; D: Transwell plate culture of JHH7 and HuH7 cells from posttreatment patients. Cells that penetrated the matrix basement membrane were stained with crystal violet; Bar = 20 μm; E: Quantification of cells in the Transwell experiment; F: Comparison of the hepatocellular carcinoma (HCC) cell death ratio; G: Collection of Annexin V/PI-stained cells and detection of the ratio of Annexin V/PI-positive cells by flow cytometry; H: Statistical analysis of the cell apoptosis ratio based on graph G-test; I and J: Detection of peptidylprolyl isomerase A expression in HCC cells by real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) (I) and Western blot (J) analysis; untreated HCC cells were used as controls; K and L: Detection of solute carrier family 29 member 3 expression in HCC cells by RT-qPCR (K) and Western blot (L); untreated HCC cells were used as controls. All cell experiments were repeated three times, and the values are expressed as the mean ± SD. ^aP value < 0.05, indicates a significant difference between the two groups with a P value < 0.05. PPIA: Peptidylprolyl isomerase A; SLC29A3: Solute carrier family 29 member 3.